Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 329

1.

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.

Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, Ernst TF, Wenderoth D.

Climacteric. 2005 Sep;8(3):251-62.

PMID:
16390757
[PubMed - indexed for MEDLINE]
2.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
3.

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A.

J Clin Oncol. 1997 Mar;15(3):955-62.

PMID:
9060533
[PubMed - indexed for MEDLINE]
Free Article
4.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.

PMID:
14753731
[PubMed - indexed for MEDLINE]
5.

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.

Palomba S, Orio F Jr, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.

Osteoporos Int. 2005 Sep;16(9):1141-9. Epub 2005 Jun 1.

PMID:
15928801
[PubMed - indexed for MEDLINE]
6.
7.

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.

Mok CC, Tong KH, To CH, Siu YP, Ma KM.

Osteoporos Int. 2008 Mar;19(3):357-64. Epub 2007 Nov 24.

PMID:
18038273
[PubMed - indexed for MEDLINE]
8.

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA.

Arthritis Rheum. 1999 Nov;42(11):2309-18.

PMID:
10555025
[PubMed - indexed for MEDLINE]
Free Article
9.

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.

Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10.

PMID:
12730746
[PubMed - indexed for MEDLINE]
10.

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators.

J Bone Miner Res. 2005 Jan;20(1):141-51. Epub 2004 Sep 29.

PMID:
15619680
[PubMed - indexed for MEDLINE]
11.

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.

Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.

J Bone Miner Res. 2009 Apr;24(4):719-25. doi: 10.1359/jbmr.081214.

PMID:
19049326
[PubMed - indexed for MEDLINE]
12.

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.

Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.

Calcif Tissue Int. 2002 Aug;71(2):103-11. Epub 2002 Jun 27.

PMID:
12085156
[PubMed - indexed for MEDLINE]
13.

A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.

Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.

Int J Clin Pract. 2008 Apr;62(4):575-84. doi: 10.1111/j.1742-1241.2008.01704.x.

PMID:
18324951
[PubMed - indexed for MEDLINE]
14.

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.

Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP.

Curr Med Res Opin. 2004 May;20(5):757-64. Erratum in: Curr Med Res Opin. 2004 Oct;20(10):1690.

PMID:
15140343
[PubMed - indexed for MEDLINE]
15.

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.

Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA.

Calcif Tissue Int. 2000 Oct;67(4):277-85.

PMID:
11000340
[PubMed - indexed for MEDLINE]
16.

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators.

Curr Med Res Opin. 2004 Dec;20(12):2031-41. Erratum in: Curr Med Res Opin. 2005 Feb;21(2):325.

PMID:
15706659
[PubMed - indexed for MEDLINE]
17.

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.

Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR.

Osteoporos Int. 2008 Jul;19(7):1039-45. Epub 2007 Dec 18.

PMID:
18087660
[PubMed - indexed for MEDLINE]
18.

A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.

Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C, Dain MP.

Bone. 1999 May;24(5):517-23.

PMID:
10321913
[PubMed - indexed for MEDLINE]
19.

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.

Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA.

J Clin Oncol. 2009 Mar 1;27(7):1047-53. doi: 10.1200/JCO.2008.19.1783. Epub 2008 Dec 15.

PMID:
19075260
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.

Osteoporos Int. 1997;7(5):488-95.

PMID:
9425508
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk